Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
gotcha..thanks for the response.
Does wikipedia report Brilacidin as active against both Gram-positive and Gram-negative class of bacteria. Gram-negative is the more resistant of the two.
Thanks for all your effort. CTIX reports Brilacidin is active against both Gram-positive and Gram-negative class of bacteria. Gram-negative bacteria are in general resistant to antibiotics.
Even with all the positive data revealed last PR this thing goes on sale. Picked up more at 2.97.
It's another buying opportunity before the fireworks.
The minimum share price for the Nasdaq Capital Market is $2. I just hope we here back and soon.
Go back to what Leo reported in Jan20 PR, Ovarian Cancer Response -- Potential Major Breakthrough in Oncology. "[bThe Principal Investigators for the Kevetrin trial have requested that the Company start preparing a presentation to be used for an article on the safety and pharmacological effect of Kevetrin on multiple cancer lines as demonstrated in the clinical trial. I believe first uplist then the article is released showing pharmacological effect of Kevetrin. Then ASCO where Dr. Geoffrey Shapiro does the presentation.
I would like to say that there has been no RS with ctix to uplist. I would mention the 1:125 RS in 2013 to pad share price of another bio company that is popular right at the moment. Getting put on the big board will be life changing for our little undervalued darling.
I read the Nasdaq update as BoD finalized and uplisting will come any day. Couple that with a major drug pipeline progressing on all cylinders couldn't ask for more.
Leo said Mar24: The data on p21 are expected to be received in mid-April. Does Leo have data in hand? if not he will very soon.
Thanks for posting the link xoc.eom
Leo has it all under control...pity the fool who strikes the rock at this point.
IMO these conferences while good for showing progression to others in the field do very little for share price if any. Upcoming material events is what brings in new investors and value. Next comprehensive update to include: Nasdaq uplisting, Increased biomarker p21 measurment at the higher dose showing reactivation of p53(hoping for more patient responses), update on increased kevetrin dosing level for eleventh cohort, B-OM possibly underway and possibly an updated Brilacidin phase3 status post FDA meeting.
Sell...no thanks I haven't been holding this three years only to miss out on seeing the promised land. Go ctix.
The last pr read "additions to the Board of Directors" I now read that as vetting of all BoD was not quite done. I would believe that once this is complete Leo will be given a firm uplisting date which would be a news worthy event.
My question is why after 6months we still wait on FDA formal meeting. Brilacidin sits on a shelf waiting on a meeting burdened sloth like government entity to back and forth with Leo. What happened to our fast track or the huge push from the administration for new antibiotics.
Will Leo put out a firm uplisting date ahead of the update? Seems like the reasonable thing to do.
I believe Leo's wording: "additions to the Board of Directors, and uplisting to the Nasdaq exchange" as a done deal. My opinion is that since these new additions were being vetted by the Nasdaq seems uplisting is a go ahead.
Material yes or no would most likely need reported. It just reads as though Leo may have been given at the very least an April date that he would receive an answer. Otherwise April will come and go.
I completely agree with the statement as a whole because he already has the trials status's but what I'm saying is that how did Leo know April 1 he would be able to update shareholders in April on Nasdaq events unless he already knew the answer. Just saying it seems like maybe Nasdaq already replied.
Leo reported on April 1 that Cellceutix will provide shareholders with a comprehensive update status on its NASDAQ uplisting in April. The comprehensive update statement sounds like Leo already has uplisting information otherwise he is just hoping to hear back from NASDAQ this month.
Retire your question about why the patient left the trial "prematurely" as you stated has been explained here 50 ways to Sunday with the best possible theory that is humanly possible. Refer back to Karen CA last response and stare at it for awhile. I might add that she left the trial for further treatment because she was well enough to do so.
I'm very bullish on ctix short and longer term. By June Leo will have received Kevetrin good news regarding p21 blood tests at higher dosage also Brilacidin FDA Phase3 blessing. Like the QIDP designation any of the above will launch share price soon.
Me too 1400, added a bit more to my Roth. Hopefully will have some real tax free gains in the near future.
They don't call it March Madness for nothing..
Don't worry next month it'll be Christmas in April in CTIX land.ha
A political connection on board doesn't hurt ether.
Stocks up 300% in three years...whats your next "credibility concern."
Hoping...love this stock and yes hope springs eternal. eom
Sure hope Leo's got a fantastic update for us Monday...Go Rally.
"The new Directors could be named any day".
Yes any day my thoughts exactly!! Thanks familyman for the reply.
Looking forward to the announcement of principles from Leo regarding the completed vetting processes. Quote from Feb5: "The names of the prospective Directors will be submitted to NASDAQ for their vetting process to ensure that the individuals meet the requirements per NASDAQ definitions. We look forward to announcing these people as the processes are completed".
Even though one of Brilacidin's key features listed in cellceutix is "active against gram negative bacteria" someone keeps posting the opposite which is very misleading.
u huh, Just doing my part. Over at Lilly, Dr. Menon played a key role in lead selection and pre-clinical development of Gemzar and Alimta, two anti-cancer drugs which have generated billions of dollars in yearly revenue. In addition, Lilly honored Dr. Menon with the prestigious President’s Recognition Award. See more at Cellceutix.com
Totally agree with having some deal lined up. Leo is not fool hearty and wouldn't risk the embarrassment of being turned down now that the wheels are in motion.
Interesting trade @3.71 for 18000+ shares @ 4.02 pm. Type Form T. Perhaps after hours spread based on news. Just a thought.
This board gives positive reinforcement or the "whiners" would have sold and moved on. Read the CHART, look at the CHART and you will see that Leo is moving this company along nicely.
To say what you want without DD evidence to back it is not prudent.
I noticed the writer of the linked article's primary interests is novel small molecule drugs, next generation vaccines, and cell therapies.
My Comment the following:
"Cellceutix has a robust pipeline of 3 drugs including the cancer drug Kevetrin currently in phase1 cohort10 at Dana Farber Cancer center with some positive results against ovarian cancer. Also a defensin mimetic antibiotic called Brilacidin having finished a very positive phase2b outcome comparing Cubicin 7 day dose regimine against Brilacidin 1 day dose for ABSSSI infection. Brilacidin preparing to start phase3 soon. Also a drug by the name of Prurisol for combating psoriasis. Prurisol is a small molecule that acts through immune modulation and has been seen to have incredible invitro results in clearing psoriasis in mouse models. Prurisol phase2 is set to begin any day"
http://www.fool.com/investing/general/2015/02/01/an-8-billion-hedge-fund-bought-this-extremely-risk.aspx#commentsBoxAnchor
Excellent response smilingra and I agree wholeheartedly. Another thing to remember is that the Brilacidin trial was double blinded, no way to get collusion.
These are stage4 patients who have not responded and have failed multiple other drugs which brought them to the Dana Farber cancer research study, patients if not for the Kevetrin study would have no hope.
Hearing first hand of such a great improvement in the health and quality of life for this once very sick Ovarian cancer patient said to be well enough now to explore further treatment is simply remarkable. More to come I'm pretty sure.